These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37783206)

  • 41. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
    Størset E; Åsberg A; Hartmann A; Reisaeter AV; Holdaas H; Skauby M; Bergan S; Midtvedt K
    Nephrology (Carlton); 2016 Oct; 21(10):821-7. PubMed ID: 26854648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
    Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
    Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
    Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunosuppression in Uterus Transplantation: Experience From the Dallas Uterus Transplant Study.
    Wilson NK; Schulz P; Wall A; Parrott M; Testa G; Johannesson L; Sam T
    Transplantation; 2023 Mar; 107(3):729-736. PubMed ID: 36445981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Case Report of the Resolution of Multiple Recalcitrant Verrucae in a Renal Transplant Recipient After a Mycophenolate Mofetil Dose Reduction.
    Ash MM; Jolly PS
    Transplant Proc; 2017; 49(1):213-215. PubMed ID: 28104140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
    Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
    Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression.
    Bernabeu-Wittel M; Naranjo M; Cisneros JM; Cañas E; Gentil MA; Algarra G; Pereira P; González-Roncero FJ; de Alarcón A; Pachón J
    Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):173-80. PubMed ID: 11957018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.
    Odorico JS; Pirsch JD; Knechtle SJ; D'Alessandro AM; Sollinger HW
    Transplantation; 1998 Dec; 66(12):1751-9. PubMed ID: 9884272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study.
    Sapir-Pichhadze R; Laprise C; Beauchamp ME; Kaouache M; Zhang X; Della Vecchia A; Azoulay L; Franco EL; Abrahamowicz M; Nicolau B
    Int J Cancer; 2024 Jun; 154(12):2043-2053. PubMed ID: 38345158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.